Table 2 Baseline Characteristics of Recipients
|  | Non-AKI by both(n = 120) | AKI by KDIGO only (n = 61) | AKI by both (n = 104) | P value (AKI by KDIGO only vs. Non-AKI by both) | P value (AKI by both vs. Non-AKI by both) | P value (AKI by KDIGO only vs. AKI by both) |
|---|---|---|---|---|---|---|
Male | 66 (55.0) | 37 (61) | 53 (51.0) | 0.5 | 0.5 | 0.2 |
 Age (years) | 46.5 ± 8.0 | 48.0 ± 9.8 | 49.1 ± 11.3 | 0.3 | 0.05 | 0.5 |
 Retransplant | 13 (10.8) | 8 (13) | 8 (7.7) | 0.7 | 0.4 | 0.3 |
 BMI (kg/m2) | 22.7 ± 3.3 | 22.8 ± 3.0 | 22.7 ± 3.6 | 0.8 | 0.9 | 0.9 |
Primary renal disease | Â | Â | Â | Â | Â | Â |
 DM | 12 (10.0) | 11 (18) | 16 (15.4) | 0.1 | 0.2 | 0.7 |
 Hypertension | 24 (20.0) | 13 (21) | 34 (32.7) | 0.8 | 0.03 | 0.1 |
 GN | 55 (45.8) | 23 (38) | 33 (31.7) | 0.3 | 0.03 | 0.4 |
 Others | 29 (24.2) | 14 (23) | 21 (20.2) | 0.9 | 0.5 | 0.7 |
 Duration of dialysis (years) | 7.1 ± 4.9 | 6.0 ± 4.1 | 6.6 ± 4.2 | 0.1 | 0.4 | 0.4 |
 PRA (%) | 13.1 ± 26.3 | 15.6 ± 29.6 | 12.3 ± 26.6 | 0.6 | 0.8 | 0.5 |
 HLA MN | 3.9 ± 1.1 | 3.8 ± 0.9 | 4.0 ± 1.3 | 0.6 | 0.4 | 0.2 |
 Cold ischemic time (minutes) | 193.2 ± 86.5 | 201.7 ± 108.7 | 230.8 ± 121.9 | 0.6 | 0.01 | 0.1 |
Induction therapy | Â | Â | Â | 0.2 | 0.01 | 0.4 |
 ATG | 10 (8.3) | 9 (15) | 21 (20.2) |  |  |  |
 Basiliximab | 110 (91.7) | 52 (85) | 83 (79.8) |  |  |  |
Immunosuppressant | Â | Â | Â | Â | Â | Â |
 Cyclosporine | 18 (15.0) | 11 (18) | 9 (8.7) | 0.6 | 0.1 | 0.08 |
 Tacrolimus | 101 (84.2) | 50 (82) | 95 (91.3) | 0.7 | 0.1 | 0.08 |
 Sirolimus | 1 (0.8) | 0 (0) | 0 (0) | 0.9 | 0.9 |  |